ReviewFrontiers in cell and developmental biology2026
GDI2 protein: research progress and its mechanisms in diseases.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SHISMA: SHape-driven inference of significant cell type-specific subnetworks from tiMe series single-cell trAnscriptomics.Bioinformatics advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GDP dissociation inhibitor 2 (GDI2), also termed RabGDIβ, is an evolutionarily conserved Rab GDP dissociation inhibitor that is broadly expressed across species and is required for fundamental cellular functions. Mechanistically, GDI2 controls the cycling of Rab small GTPases between membranes and the cytosol, thereby regulating Rab-dependent membrane targeting, intracellular trafficking, and downstream signal transduction. Increasing evidence indicates that GDI2 is not only a constitutive component of the membrane-transport machinery; aberrant GDI2 expression or activity is associated with diverse human diseases. Notably, the functional consequences of GDI2 dysregulation appear to be context dependent, with reported involvement in cancer, neurodegeneration, immune dysregulation, and metabolic disease. Here, we synthesize current knowledge of GDI2 biology, highlighting recent advances that delineate its molecular features and its roles in maintaining membrane-trafficking homeostasis, remodeling signaling networks, and shaping disease-relevant cellular phenotypes. We also discuss the translational implications of GDI2 as a potential diagnostic biomarker and therapeutic target, and we propose a conceptual framework to guide mechanistic interpretation and the development of GDI2-directed therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.